MARKET

ADXS

ADXS

Advaxis Inc
OTCQX
2.180
-0.010
-0.46%
Closed 14:43 09/30 EDT
OPEN
2.000
PREV CLOSE
2.190
HIGH
2.280
LOW
2.000
VOLUME
1.67K
TURNOVER
3.72K
52 WEEK HIGH
56.80
52 WEEK LOW
1.020
MARKET CAP
3.97M
P/E (TTM)
-0.2444
1D
5D
1M
3M
1Y
5Y
Advaxis GAAP EPS of -$3.83
Advaxis  press release (<a href="https://seekinga...
Seekingalpha · 09/13 04:49
Advaxis Updates on the Phase 1 Clinical Trial of ADXS-504 for the Treatment of Early Prostate Cancer
Evaluation completed of first dose level in investigator-sponsored study in biochemically recurrent prostate cancer Enrollment initiated for second dose level MONMOUTH JUNCTION, N.J., June 29, 2022 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinic...
GlobeNewswire · 06/29 12:00
Advaxis to implement one-for-80 reverse split
Advaxis (OTC:ADXS -13.8%) to implement a one-for-80 reverse split of its issued and outstanding common stock . The reverse stock split will become effective as of 12:00am ET on June 6,
Seekingalpha · 06/03 20:38
Advaxis, Inc. Announces 1-for-80 Reverse Stock Split
MONMOUTH JUNCTION, N.J., June 03, 2022 (GLOBE NEWSWIRE) -- Advaxis, Inc. (OTCQX: ADXS) (the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that it has filed a C...
GlobeNewswire · 06/03 20:05
Advaxis to Present Updated Clinical and Immunogenicity Data from Ongoing Phase 1/2 Trial of ADXS-503 in Metastatic Non-Small-Cell Lung Cancer (NSCLC) and Study Design of ADXS-504 Trial in Early Prostate Cancer at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting
Overall response rate of 14% and disease control rate of 36% in Part B of ADXS-503 trial with durable clinical benefit as an add-on therapy to patients with prior disease progression on KEYTRUDA® (pembrolizumab) Updated data continue to show disease contro...
GlobeNewswire · 05/26 21:00
BRIEF-Advaxis Applies To List Common Stock On Nasdaq Under Symbol "ADXS" - SEC Filing
reuters.com · 05/12 21:37
Advaxis to Present at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting
MONMOUTH JUNCTION, N.J., April 27, 2022 (GLOBE NEWSWIRE) -- Advaxis, Inc. (OTCQX: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that it will present data from the P...
GlobeNewswire · 04/27 14:00
Advaxis Announces Publication of ADXS-PSA Data in The Oncologist
ADXS-PSA in combination with KEYTRUDA® in metastatic castration-resistant prostate cancer (mCRPC) is associated with prolonged overall survival in this population, particularly in patients with visceral metastasis Median overall survival of 16.4 months for...
GlobeNewswire · 04/08 12:00
More
About ADXS
Advaxis, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of Listeria monocytogenes (Lm)-based antigen delivery products. The Company is using its Lm platform directed against tumor-specific targets to engage the patient's immune system to destroy tumor cells. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins. Its Lm platform technology has clinical activity in several programs. These Lm strains integrate multiple functions into a single immunotherapy as they access and direct antigen presenting cells to stimulate anti-tumor T-cell immunity, stimulate and activate the immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the tumor microenvironment (TME) to enable the T-cells to eliminate tumors.

Webull offers kinds of Advaxis, Inc. stock information, including OTCQX:ADXS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ADXS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ADXS stock methods without spending real money on the virtual paper trading platform.